pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 14·1 min read
save

MRI Features That Suggest Diffuse Midline Glioma Highlighted in Expert Discussion

May 14, 2026·read at onclive ↗Neutral

In a recent educational segment, Dr. Chong introduced the clinical scenario where patients with suspected brain tumors are first evaluated with imaging before tissue sampling.

He then asked Dr. Shonka to describe how MRI findings can help clinicians suspect diffuse midline glioma, a rare and aggressive tumor.

Dr. Shonka highlighted that specific patterns on MRI, such as location in the midline structures and characteristic signal changes, can raise the index of suspicion and guide further diagnostic steps.

The conversation underscored the importance of recognizing these imaging clues early, as they influence the decision to obtain tissue for definitive diagnosis.

source

This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.

Original headline: “Imaging Clues That Raise Suspicion for Diffuse Midline Glioma”

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
topics
Glioblastoma2OncologyRare Disease

related stories

  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Sep 10Encoded raises $275M series F for Dravet syndrome gene therapyBioSpace
  • Sep 8BrainChild Bio targets deadly pediatric brain cancer with $116M series ABioSpace
  • Sep 8BrainChild hauls in $116M to make cell therapies for childhood brain cancersBioPharma Dive
  • Sep 7BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancerFierce Biotech